Analysis for effect of Eicosapentaenoic acid (EPA) on aberrant crypt foci (ACF)

Analysis for effect of Eicosapentaenoic acid (EPA) on aberrant crypt foci (ACF) - Analysis for effect of EPA on ACF

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001551

Enrollment

100

Registered

2009-02-01

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with aberrant crypt foci (ACF)

Interventions

Oral administration of EPA 600mg three times daily for one month. No administration of newly drug for one month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a. Obtaining informed consent b. Positive for ACF

Exclusion criteria

Exclusion criteria: a. Liver cirrhosis or chronic hepatic, chronic renal failure b. Women who are pregnant or with a possibility of pregnancy c. Alcohol dependence or drug dependence d. Drug allergy e. Heart failure f. Hemorrhagic g. Those who have started to use other medication or dietary supplement in study period h. The patient that it is already taken EPA i. History of colorectal cancer j. Family history of colorectal cancer k. The patient currently taking NSAIDs l. Inadequate to entry to this study

Design outcomes

Primary

Measure	Time frame
Observation of ACF and polyps using magnifying endoscopy	—

Countries

Japan

Contacts

Public ContactHirokazu Takahashi

Yokohama City University Graduate School of Medicine Gastroenterology Division

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026